Ignota Labs has acquired the clinical pipeline of Kronos Bio following setbacks that led to Kronos’s departure from public markets. This acquisition underlines Ignota's innovative approach to rehabilitating drug candidates that were previously shelved. The strategy aims to leverage existing assets by applying new scientific insights and development tactics, potentially reinvigorating therapies for clinical advancement.